A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. After the ...

The rapid rise of GLP-1 weight loss drugs such as semaglutide and tirzepatide has created two parallel markets. One market consists of FDA-approved products used under typical prescribing conditions.

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses. About one in every eight U.S. adults is currently taking a ...